

COVID-19 Vaccine Quick Reference Guide

Interim Clinical Considerations Regarding Vaccination

Pfizer-BioNTech	Moderna	Janssen
<ul style="list-style-type: none">• Number of Doses: Two• Interval between doses: 21 days• mRNA vaccine	<ul style="list-style-type: none">• Number of Doses: Two• Interval between doses: 28 days• mRNA vaccine	<ul style="list-style-type: none">• Number of Doses: One• Interval between doses: N/A• Viral vector

Vaccine Information

- Authorized age groups:
 - Pfizer-BioNTech ≥ 16 years old
 - Moderna ≥ 18 years old
 - Janssen ≥ 18 years old
- Administered by an intramuscular injection as either a two-dose series or single dose.
- None of the current authorized vaccines contain live virus.

Interchangeability between different COVID-19 vaccines

- These products are not interchangeable. Every effort should be made to determine which vaccine product was received as the first dose to ensure completion of the vaccine series with the same product.
- In situations where the same mRNA vaccine product is temporarily unavailable, it is preferable to delay the 2nd dose (up to 6 weeks) to receive the same product than to receive a mixed series using a different product.
- In exceptional situations where a first dose mRNA product is no longer available or cannot be determined, any available mRNA vaccine may be administered at a minimal interval of 28 days.
- If two doses of different mRNA COVID-19 vaccine products are administered in these situations (or inadvertently), no additional doses of either product are recommended at this time.
- In exceptional situations where the first dose mRNA product is not available or due to a contraindication, a single dose of Janssen may be considered at minimal interval of 28 days.

Coadministration with other vaccines

- Data is currently insufficient on safety and efficacy of COVID-19 vaccines administered simultaneously with other vaccines.
- Current recommendation is to administer COVID-19 vaccines alone, with a minimal interval of 14 days before or after administration of any other vaccine.
- If the benefits of vaccination outweigh potential unknown risks of coadministration (e.g., tetanus or rabies) or to avoid barriers or delays to COVID-19 vaccination, a shorter period situation may be considered.

COVID-19 Vaccine Candidates

- Individuals with prior history of COVID-19 infection: safe to vaccinate.
- Individuals with current COVID-19 infection: vaccination should be deferred until acute illness is resolved and they have met criteria to discontinue isolation. This also applies to individuals who acquire infection in between COVID-19 dose series.
- Individuals who previously received passive antibody therapy for COVID-19: Vaccination should be deferred for at least 90 days. This does not apply to antibody therapy administered for other conditions, such as arthritis or cancer.
- Polyethylene glycol (PEG) is an ingredient in both mRNA vaccines and polysorbate 80 is an ingredient in Janssen.
 - These ingredients are structurally similar and cross reaction sensitivity may occur
 - Individuals with a contraindication to mRNA vaccine may be able to receive Janssen, and vice versa-see precautions below.

Management of post-COVID-19 Vaccine Symptoms

- Antipyretic or analgesic medications can be taken for treatment of post vaccination local or systemic symptoms if clinically appropriate. Routine, prophylactic administration is not recommended at this time.

Precautions and Contraindications to COVID-19 Vaccination

CONTRAINDICATION TO VACCINATION	PRECAUTION TO VACCINATION	MAY PROCEED WITH VACCINATION
<p>History of the following:</p> <ul style="list-style-type: none"> • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to component of the vaccine† • Immediate allergic reaction* of any severity after a previous dose or known (diagnosed) allergy to a component of the vaccine† 	<p>Among people without a contraindication, a history of:</p> <ul style="list-style-type: none"> • Any immediate allergic reaction* to other vaccines or injectable therapies‡ <p>Note: people with a contraindication to mRNA COVID-19 vaccines have a precaution to Janssen COVID-19 vaccine, and vice versa. See footnote for additional information on additional measures to take in these people.#</p>	<p>Among people without a contraindication or precaution, a history of:</p> <ul style="list-style-type: none"> • Allergy to oral medications (including the oral equivalent of an injectable medication) • History of food, pet, insect, venom, environmental, latex, etc., allergies • Family history of allergies
<p>Actions:</p> <ul style="list-style-type: none"> • Do not vaccinate. • Consider referral to allergist-immunologist. • Consider other vaccine alternative.† 	<p>Actions:</p> <ul style="list-style-type: none"> • Risk assessment • Consider referral to allergist-immunologist • 30-minute observation period if vaccinated 	<p>Actions:</p> <ul style="list-style-type: none"> • 30-minute observation period: people with history of anaphylaxis (due to any cause) • 15-minute observation period: all other people

If you have any questions regarding COVID-19 vaccination, please contact your Remedi SeniorCare Account Manager or Consultant Pharmacist